1. Pink Sheet
  3. >>Clinical Trials

New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma

 
• By Emily Hayes

Early data from small studies presented at the Society of Melanoma Research meeting suggest potential for safely and effectively combining PD-1 inhibitors with a range of drugs, including Amgen’s Imlygic vaccine.

SAN FRANCISCO – Early data support the use of new combinations including PD-1 immunotherapies in melanoma, at a time when the field is still working out how to use the new options already available.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D